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Background: Oral sodium supplementation of CF infants is not standard practice
in the UK [1]. Sub clinical salt depletion can result in growth impairment in CF,
particularly in infancy [2]. Infant formulas and breast milk may not meet the sodium
requirements of CF infants.
Method: The urinary electrolyte levels of all infants diagnosed during 2008 with
CF at RHSC was measured. Spot urine analysis was measured once the infant was
established on feeds. A low result is classed as a urinary sodium level less than
10mmol/L or a sodium:potassium ratio less than 2:1. Sodium supplementation
consisted of a 30% sodium chloride solution (5mmols sodium/1ml).
Results: In total 10 infants were diagnosed with CF, 7 on newborn screening,
2 with meconium ileus and 1 with hyperbilirubinaemia. 8 of the infants were
homozygous for the DF508 mutation. 9 of the infants were pancreatic insufﬁcient
and started pancreatic enzymes. 5 of the infants were breast fed and 5 were formula
fed (one with a hydrolysed formula and one a MCT formula). All infants had
urinary electrolytes measured and all were found to be sodium depleted. Sodium
supplementation was commenced on all infants apart from the infant who was
pancreatic sufﬁcient whose growth was on the 91st centile. The dose of sodium
supplementation required to bring the urinary sodium into the normal range was
between 0.6mmol/Kg to 6mmol/Kg. Improvement in growth was noted in 6 of the
infants after commencement of supplements.
Conclusion: These results suggest infants diagnosed with CF in the UK are at
risk of sodium depletion. Routine sodium supplementation should be considered in
those with low urinary electrolyte levels.
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Background: Malnutrition in CF is commonly associated with deﬁciencies of iron,
trace elements and fat soluble vitamins. Since CF is also associated with chronic
inﬂammation in many patients and increasing with age, diagnosing iron deﬁciency
(ID) might be difﬁcult. Soluble transferrin receptor (sTfR) is a marker for iron
status that is independent of inﬂammation.
Aim: To evaluate if more patients are diagnosed with ID when including sTfR in
the annual review.
Method: During the annual review iron status and inﬂammatory variables are
measured including hemoglobin, MCV, ferritin, transferrin saturation, ESR, CRP,
haptoglobin. If 2 out of 3 results from MCV, ferritin and transferrin saturation are
lower than ref. values the patient is regarded as ID (“old” deﬁnition). During 2007
sTfR was also included in the annual review. If sTfR was above ref.values and
at least one of the regular measurements mentioned above was low, these patients
were also regarded as an ID (“new”).
Results: 134 patients (56F) with a mean age 21.6±12.7 yrs were included. FEV1.0
were 77±24% in adults and 90±17% in children. Twenty-ﬁve patients had ESR
above 13mm and 26 had CRP above 5mg/L. sTfR was not correlated to any
inﬂammatory variable.
Only 2/134 patients had anaemia, both being ID. With the “old” deﬁnition 11 pa-
tients were ID (3F, median age 17.8, range 4.4−33.6 yrs). By adding sTfR another
2 patients were diagnosed as ID. Two out of the 6 patients with increased sTfR had
no other sign of ID.
Conclusion: 11 patients (8%) of the population had ID according to the old
diagnostic criteria. The addition of sTfR only recognised another 2 patients (10%).
The proportion of patients with severe inﬂammation was relatively low which may
have inﬂuenced the outcome. The use of only sTfR as indicator of ID cannot be
recommended in CF.
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Background: Patients with CF are at risk of an impaired Vitamin K status which
may lead to frank deﬁciency and adversely affect blood coagulation and bone
formation/density.
Objectives: (1) To establish the prevalence of frank Vitamin K deﬁciency and
suboptimal Vitamin K status in children with CF.
(2) To evaluate the effectiveness of age related doses of Vitamin K on a weekly
basis to correct a suboptimal Vitamin K status and a daily basis for frank deﬁciency.
Patients and Methods: 31 children with PI CF and 2 children with pancreatic
sufﬁcient (PS) CF had base line data collected for serum PIVKA II and serum
Vitamin K1. Children with a suboptimal Vitamin K1 (Vitamin K1 <0.15ug/l)
received an age related weekly dose of Phytomenadione (Vitamin K1) (10mg for
those over 2years (n = 32) and a 5mg for those under 2 years (n = 1)). Children with
frank Vitamin K deﬁciency (raised PIVKA II >0.2au/ml) received a daily dose of
10mg Phytomenadione (n = 5, all over 2 years of age).
After 1 year the baseline blood tests were repeated. None of the children had
previously received Vitamin K supplementation.
Results: Sixteen children (48%) had a compromised Vitamin K status. Of these
patients 5 (15%) had frank Vitamin K deﬁciency and 11 (33%) had a suboptimal
Vitamin K1 level.
Administration of Phytomenadione (Vitamin K1) as per the protocol corrected all
the children with either frank Vitamin K deﬁciency or suboptimal Vitamin K status.
(2 samples were lost).
Both PS children with CF had suboptimal Vitamin K levels but were not frankly
deﬁcient.
Conclusion: Children with PI CF are more likely to have a suboptimal Vitamin K
status than a frank deﬁciency and this can be corrected with an age related weekly
dose of Vitamin K.
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Cystic ﬁbrosis (CF) patients are at high risk for developing vitamin K deﬁciency
and are commonly supplemented with this vitamin. Since methods dedicated for
monitoring vitamin K status are hardly available, the data related to the efﬁcacy
of the supplementation are sparse. Therefore, we have aimed to assess vitamin K
status of our routinely supplemented patients.
Material and Methods: The study comprised 42 CF patients aged from 3 to
33 years supplemented at least once a week. Vitamin K status was assessed by the
measurement of PIVKA II concentrations (ELISA, Roche Diagnostic, Poland).
Results: In 30 patients PIVKA II concentrations were lower than detection limit
provided by the manufacturer (<4ng/mL), suggesting normal vitamin K status. In
12 (28.6%) subjects this undercarboxylated protein was detectable (range of 5 to
97 ng/mL).
Conclusions: Despite vitamin K supplementation its deﬁciency in CF patients is
still frequent.
